Endotoxin Activity Assay as a Novel Predictor of Disease Progression in Patients With Mild Cholangitis
In Vivo · 2025
DOI: 10.21873/invivo.13970 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift In Vivo, 2025. Verfasst von Koichi Mori und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Hauptthemen laut MEDLINE: Cholangitis, Endotoxins. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: Acute cholangitis is a critical biliary infection that can swiftly evolve into sepsis and organ failure. Certain patients with mild acute cholangitis might advance to a more severe status. Identifying predictive factors for such exacerbation is of paramount importance. This study aimed to investigate whether the endotoxin activity assay (EAA) could serve as a predictive biomarker for the progression of mild acute cholangitis. PATIENTS AND METHODS: We conducted a retrospective observational study at Yokohama City University Hospital, enrolling 200 patients hospitalized with acute cholangitis between May 2011 and June 2015. Patients with initially mild acute cholangitis were stratified into two groups based on their severity on Day 1: the stable group (remaining mild) and the exacerbation group (progressing to moderate/severe cholangitis). Clinical parameters were analyzed to assess risk factors for exacerbation. RESULTS: Among 74 patients with mild acute cholangitis at admission, 33 (44.6%) progressed to moderate/severe cholangitis within 24 h. Multivariate logistic regression analysis identified chemotherapy within 28 days [odds ratio (OR)=3.440, 95% confidence interval (CI)=1.170-10.100, p=0.025], serum albumin levels (OR=0.303, 95%CI=0.094-0.975, p=0.045), and EAA ≥0.4 (OR=3.880, 95%CI=1.210-12.500, p=0.023) as independent predictors of disease exacerbation. A predictive equation was developed using the logistic regression model: log (P/1-P)=3.285-1.265×Alb (mg/dl) + 1.291 × (Chemotherapy within 28 days) +1.343 × (EAA ≥0.4) (P: the probability of exacerbation). CONCLUSION: EAA was identified as the most significant factor for exacerbating mild acute cholangitis. The combination of EAA, albumin levels, and a history of chemotherapy within the past 28 days suggests the potential to predict the progression of mild acute cholangitis to a more severe form.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
- Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan kmkmkm@yokohama-cu.ac.jp.
Zitieren
APA
Mori, K., Miyake, K., Matsuyama, R., Goto, K., Arisaka, S., Suwa, Y., Kadokura, T., Homma, Y., & Endo, I. (2025). Endotoxin Activity Assay as a Novel Predictor of Disease Progression in Patients With Mild Cholangitis. In Vivo. https://doi.org/10.21873/invivo.13970
Vancouver
Mori K, Miyake K, Matsuyama R, Goto K, Arisaka S, Suwa Y, et al. Endotoxin Activity Assay as a Novel Predictor of Disease Progression in Patients With Mild Cholangitis. In Vivo. 2025. doi:10.21873/invivo.13970
BibTeX
@article{Mori2025,
author = {Mori, Koichi and Miyake, Kentaro and Matsuyama, Ryusei and Goto, Koki and Arisaka, Sayaka and Suwa, Yusuke and Kadokura, Toshiaki and Homma, Yuki and Endo, Itaru},
title = {Endotoxin Activity Assay as a Novel Predictor of Disease Progression in Patients With Mild Cholangitis},
journal = {In Vivo},
year = {2025},
doi = {10.21873/invivo.13970}
}
EUVIMED